Drug recall · July 3, 2024
Duloxetine Delayed-Release Capsules recall
Why: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, a) 30 capsules bottles, NDC 60429-165-30; b) 90 capsules bottles, NDC 60429-165-90, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Packaged by GSMS, Incorporated, Camarillo, CA 93012.
- Lots / codes
Lot: a) GS045371, Exp: 01/31/2025; b) GS045910, Exp. 01/31/2025
- Quantity
- 21,655 (30 count bottle), 34,149 (90 count bottle)
- Company
- Golden State Medical Supply Inc., Camarillo, CA
- Distribution
- Nationwide in the U.S.
- Initiated
- May 13, 2024 · Voluntary: Firm initiated
- Classified
- June 25, 2024
- Reported
- July 3, 2024
- Ended
- March 20, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Duloxetine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.